ISSN 1662-4009 (online)

Previous issue | Volume 21 | ESPEYB21

Yearbook of Paediatric Endocrinology 2024

10. Type 1 Diabetes

Clinical Trials – New Treatments

ey0021.10-1 | Clinical Trials – New Treatments | ESPEYB21

10.1. Baricitinib and beta-cell function in patients with new-onset type 1 diabetes

M Waibel , JM Wentworth , M So , JJ Couper , FJ Cameron , RJ MacIsaac , al. et

Brief Summary: This phase 2, double-blind, placebo-controlled trial, randomized 91 people (10-30 years-old) diagnosed with type 1 diabetes (T1D) within the previous 100 days to receive either oral baricitinib (n=60) or placebo (n=31) for 48 weeks. Baricitinib was safe and preserved the capacity of β-cells to secrete insulin.Baricitinib is a Janus kinase (JAK) inhibitor blocking cytokine signalling and is already an effective disease-modifying treatm...

ey0021.10-2 | Clinical Trials – New Treatments | ESPEYB21

10.2. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes

EL Ramos , CM Dayan , L Chatenoud , Z Sumnik , KM Simmons , A Szypowska , al. et

Brief Summary: This double-blind, multicenter trial randomized 328 children and adolescents (8-17 years-old) diagnosed with type 1 diabetes (T1D) within the past 6 weeks to receive either teplizumab or placebo for two 12-day courses. Teplizumab increased stimulated C-peptide levels after 1.5 years, indicating better preservation of β-cell function.Teplizumab is a monoclonal antibody that binds to CD3 on the surface of T-cells, thereby reducing the i...

ey0021.10-3 | Clinical Trials – New Treatments | ESPEYB21

10.3. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial

L Krogvold , IM Mynarek , E Ponzi , FB Mork , TW Hessel , T Roald , al. et

Brief Summary: The Diabetes Virus Detection (DiViD) Intervention phase 2, placebo-controlled, double-blind trial randomized 96 children and adolescents (age 6-15 years) with new-onset type 1 diabetes (T1D) to receive either the antivirals, Pleconaril and Ribavirin, (n=47) or placebo (n=49) for 6 months. The antiviral treatment improved β-cell function at 12 months, and it was well tolerated and safe.Viral infections, particularly enteroviruses, have...